Oppenheimer Maintains Perform on Legend Biotech, Lowers Price Target to $25
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Perform and lowers the price target from $40 to $25.
Oppenheimer analyst Kostas Biliouris maintains Legend Biotech (NASDAQ:LEGN) with a Perform and lowers the price target from $40 to $25.